· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print) 2019 / N 4 Дуаклир Дженуэйр в терапии хронической обструктивной болезни легких: особенности назначения Н.П. Княжеская, М.А. Макарова, Т.Н. Карнозова, А.С. Белевский References 1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 Report. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf Accessed 2019 Dec 12. 2. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D,Andrea P, Arrasate C, Chen H, Banerji D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. The Lancet. RespiratoryMedicine 2013 May;1(3):199-209. 3. Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clinics in Chest Medicine 2014 Mar;35(1):157-63. 4. Martinez FJ, Fabbri LM, Ferguson GT, Orevillo C, Darken P, Martin UJ, Reisner C. Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest 2017 Dec;152(6):1169-78. 5. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Current Medical Research and Opinion 2009 Aug;25(8):2043-8. 6. Marth K, Schuller E, Pohl W. Improvements in patient-reported outcomes: a prospective, non interventional study with aclidinium bromide for treatment of COPD. Respiratory Medicine 2015 May;109(5):616-24. 7. D’Urzo A, Kerwin E, Rennard S, He T, Gil EG, Caracta C. One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice daily aclidinium bromide in patients with COPD. COPD 2013 Aug;10(4):500-10. 8. Kerwin EM, D`Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators. Efficacy and safety of 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012 Apr;9(2):90-101. 9. Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, Caracta CF. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chromic obstructive pulmonary disease patients. Clinical Drug Investigation 2013 Dec;33(12):893-904. 10. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E. Efficacy and safety of treatment with twice-daily aclidinium bromide in COPD patients: the ATTAIN study. The European Respiratory Journal 2012 Oct;40(4):830-6. 11. Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C; LAS-MD-35 study investigators. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respiratory Medicine 2013 Dec;107(12):1957-65. 12. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sciences 1993;52(26):2145-60. 13. Molimard M, Naline E, Zhang Y, Le Gros V, Begaud B, Advenier C. Long- and short-acting beta2 adrenoreceptor agonists: interactions in human contracted bronchi. The European Respiratory Journal 1998 Mar;11(3):583-8. 14. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G; Formoterol in Chronic Obstructive Pulmonary Disease I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. The American Journal of Respiratory and Critical Care Medicine 2001 Sep;164(5):778-84. 15. D’Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respiratory Research 2014 Oct;15(1):123. 16. Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, Caracta C, Gil EG, Leselbaum A. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulmonary Medicine 2014 Nov;14:178. 17. Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chromic Obstructive Pulmonary Disease 2017 Aug;12:2545-58. 18. Donohue JF, Soong W, Wu X, Shrestha P, Lei A. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD. Respiratory Medicine 2016 Jul;116:41-8. 19. van der Palen J, Ginko T, Kroker A, van der Valk P, Goosens M, Padullés L, Seoane B, Rekeda L, Garcia Gil E. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opinion on Drug Delivery 2013 Aug;10(8):1023-31. 20. Chrystyn H, Niederlaender C. The Genuair inhaler: a novel, multidose dry powder inhaler. International Journal of Clinical Practice 2012 Mar;66(3):309-17. 21. García-Río F, Soler-Cataluña JJ, Alcazar B, Viejo JL, Miravitlles M. Requirements, strengths and weaknesses of inhaler devices for COPD patients from the expert prescribers’ point of view: results of the EPOCA Delphi consensus. COPD 2017 Dec;14(6):573-80.    [ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]